Paraneoplastic cerebellar degeneration
ORPHA:623626DiseaseAll ages
Фенотипы (HPO)24
Частый (30–79%)4
HP:0001251Ataxia
HP:0002922Increased CSF protein concentration
HP:0012229CSF pleocytosis
HP:6000397CSF oligoclonal immunoglobulin G bands
Периодический (5–29%)20
HP:0000639Nystagmus
HP:0000651Diplopia
HP:0001260Dysarthria
HP:0001272Cerebellar atrophy
HP:0002015Dysphagia
HP:0002017Nausea and vomiting
HP:0002315Headache
HP:0002317Unsteady gait
HP:0011134Low-grade fever
HP:0012189Hodgkin lymphoma
HP:0033834Malaise
HP:0100013Neoplasm of the breast
HP:0100543Cognitive impairment
HP:0100615Ovarian neoplasm
HP:5000006Anti-CV2/CRMP5 antibody positivity
HP:5000016Anti-Hu antibody positivity
HP:5000024Anti-mGluR1 antibody
HP:5000030Anti-Ri antibody
HP:5000034Anti-Tr/DNER antibody
HP:5000037Anti-Yo antibody positivity
Эпидемиология6
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 1 000 000 | 0.9553 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.2225 | Europe | Value and class |
| Point prevalence | 1-9 / 1 000 000 | 0.6869 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.2236 | Italy | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.285 | Italy | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)